First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab

Submitted by admin on September 13, 2021 - 10:26am

Source:

Pharmaforum

News Tags:

Novartis

tiselizumab

FDA

esophageal cancer

BeiGene

Headline:

First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab

snippet:

Novartis has filed for FDA approval of tislelizumab – a PD-1 inhibitor licensed from Chinese biotech BeiGene earlier this year – as a second-line treatment for oesophageal cancer.

Search form

You are here

First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab

First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab